FCGRT and myasthenia gravis: Before Efgartigimod was developed and approved, Myasthenia gravis was treated with high doses of IVIg to saturate all FcRn molecules with high concentrations of IgGs thereby limiting the recycling of all IgGs and, thus, increasing IgG clearance [45].